Search
Doxapram
go.drugbank.com/drugs/DB00561ApprovedInvestigationalVet approved(From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
Dextropropoxyphene
go.drugbank.com/drugs/DB00647ApprovedIllicitWithdrawnDue to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. … The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect.
Mixtures: Darvocet-N 50, Darvocet-N 100Products: Darvon-NMibefradil
go.drugbank.com/drugs/DB01388ApprovedWithdrawnMibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.
Erythrityl tetranitrate
go.drugbank.com/drugs/DB01613ApprovedWithdrawn(From Martindale, The Extra Pharmacopoeia, 30th ed, p1020)
Risdiplam
go.drugbank.com/drugs/DB15305ApprovedInvestigational[L15331,L15336] Set to be substantially cheaper than other available SMA therapies,[L15351] risdiplam appears to provide a novel and relatively accessible treatment option for patients with SMA regardless
Vonicog alfa
go.drugbank.com/drugs/DB12872ApprovedInvestigationalVonicog alfa is a recombinant human von Willebrand factor (rVWF) produced from Chinese hamster ovary cells.
Acetylcarnitine
go.drugbank.com/drugs/DB08842ApprovedInvestigationalIn human plasma and tissues, acetylcarnitine is the most predominant acylated ester of carnitine, which is an amino acid derivative that is made in the kidney, liver, and brain from lysine and methionine
DL-Methylephedrine
go.drugbank.com/drugs/DB11278ApprovedMethylephedrine is not legally available in the United States, but has been identified in cases of drug abuse [L2836].
Synonyms: N-methylephedrine DL-form, (+/-)-N-methylephedrineNOX-700
go.drugbank.com/drugs/DB05464ExperimentalNOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). … It has since been found that oxidative signaling of the redox-sensitive transcription factor, NF-κB, and inhibiting protein glycation are responsible for the drug's therapeutic effects.
Canakinumab
go.drugbank.com/drugs/DB06168ApprovedInvestigationalboth part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). … Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are